OP0278-PARE The french patient's association (AFLAR: french league against rheumatism) has generated the french national alliance against osteoarthritis and the first general convention of osteoarthritis in france: a campaign to create a national lobbying tool to improve the management of osteoarthritis. (15th June 2017)

• Record Type: Journal Article
• Authors: Grange, L; Rannou, F; Berenbaum, F; Roques, C; Srour, F; Delaunay, C; Niemczynsky, P; Dreux, C; Richette, P; Joseph, P-A; Cochet, C; Giraud, J; Launois, F Alliot; Gérard, C
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 171
• Page End: 172
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.1464
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: OA suffers from a lack of interest and not considered serious enough by Health authorities taking into account the burden of the disease. AFLAR has fostered dynamics by creating a structure called the National Alliance against OA, includes national experts, patients and health professionals (HP). A initiative of this group has been to organize the first General Convention for OA. Objectives: Its main challenge was to provide a list of actions that could potentially change the face of the disease and improve the visibility of OA along with the needs and demands from French patients. Methods: 10 regional roundtables (with HP, patients and health institutions, around five topics) has been launched with discussions and debates and enabled the production of patient-related proposals in order to improve their care and information. Results: 79 proposals have been selected and submitted to an online vote in order to be prioritized. Among the 5 topics addressed by the regional roundtables, cross-cutting issues were identified and 9 fields of action emerged. The final proposals were synthesized in a White Paper document and presented to the national Senate assembly. After it was broadcast to the health and public authorities in a prospect of lobbying. see in the image. Conclusions: Although the impact of this initiative is not yet measurable, we think that it should improve the awareness of the decision-makers on the burden of the disease and provide concrete ideas to governmental and non-governmental policy makers in order to improve the quality of life of OA patients. Acknowledgements: L. Euller-Ziegler F. Blanchet F. Beroud CE Bouvier D.Romain Bertholon, SANOIA, SNMR, CFMR. With support of Genévrier, Pierre Fabre, Expanscience Rottapharm Meda laboratory, SOFMER, CONMK & AFLAR Disclosure of Interest: None declared